研究者詳細 - 成田　伸太郎

研究等業績 - その他 - 成田　伸太郎

分割表示 680 件中 441 - 460 件目／全件表示 >>

Cystometric evaluation of recovery in hypocompliant defunctionalized bladder as a result of long-term dialysis after kidney transplantation.

Takamitsu Inoue, Shigeru Satoh, Takashi Obara, Mitsuru Saito, Kazuyuki Numakura, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi

International journal of urology : official journal of the Japanese Urological Association 23 ( 8 ) 694 - 700 2016年08月

OBJECTIVES: To evaluate the functional recovery of a pretransplant hypocompliant bladder in patients without neurological disorders, and to determine its relationship with ureteral complications, including vesicoureteral reflux. METHODS: A total of 61 patients without neurogenic disorders, who underwent video water cystometry pre- and 1 year post-transplantation, were enrolled. Cystometric bladder capacity and maximum intravesical pressure were measured, and compliance was calculated by the elevation in intravesical pressure as a result of an increase in volume. The frequencies of urinary complications, including urinary leakage, pyelonephritis and vesicoureteral reflux, were also evaluated. RESULTS: Pretransplant dialysis duration correlated with pretransplant bladder capacity and compliance (R(2) = 0.421, P < 0.001 and R(2) = 0.418, P < 0.001, respectively). A total of 16 (26.2%) patients had hypocompliant bladders <10 mL/cmH2 O, whereas 10 of the 12 patients (83.3%) with pretransplant dialysis duration of more than 5 years had a pretransplant hypocompliant bladder. Bladder compliance significantly recovered to >20 mL/cmH2 O (21.1-286.0) at 1 year post-transplantation in all 16 patients with a pretransplant hypocompliant bladder. No significant differences were observed for urinary leakage, pyelonephritis or vesicoureteral reflux between patients with and without a pretransplant hypocompliant bladder. CONCLUSIONS: Bladder compliance decreases logarithmically pretransplantation according to dialysis duration. Although the ability of the patients to recover varies, dysfunctions associated with a pretransplant hypocompliant bladder recover to normal ranges after renal transplantation. A pretransplant hypocompliant bladder seems not to be associated with the post-transplant prevalence of urinary complications or vesicoureteral reflux.

DOI PubMed

当院における去勢抵抗性前立腺癌に対する新規内分泌療法エンザルタミド・アビラテロンの初期使用成績

喜早祐介, 成田伸太郎, 鶴田大, 前野淳, 齋藤満, 井上高光, 土谷順彦, 佐藤滋, 羽渕友則

泌尿器外科 ( 医学図書出版(株) ) 29 ( 8 ) 1279 - 1282 2016年08月

去勢抵抗性前立腺癌に対し、新規内分泌療法としてエンザルタミド(Enza)およびアビラテロン酢酸エステル(Abi)を使用した26例の初期使用成績を検討した。Enza 21例、Abi 17例に投与し、PSA 50%低下率はEnza 33.3%、Abi 17.6%であり、いずれの治療も重篤な副作用は認めなかった。今後症例を重ね、最適な投与患者選択と投与タイミングの検討が必要と考えられた。(著者抄録)

[Extrarenal Retroperitoneal Angiomyolipoma Masquerading as Retroperitoneal Liposarcoma : A Report of Two Cases].

Ryohei Yamamoto, Takamitsu Inoue, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Shintaro Narita, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi

Hinyokika kiyo. Acta urologica Japonica 62 ( 6 ) 317 - 22 2016年06月

We report two patients with extrarenal retroperitoneal angiomyolipoma masquerading as perinephric liposarcoma. Patient 1 : A 66-year-old man was diagnosed with a retroperitoneal tumor near the right renal hilum on an abdominal computed tomography (CT) performed before surgery for gastric cancer. A diagnosis of extrarenal retroperitoneal angiomyolipoma was made on the basis of negative uptake of fluorine- 18 2-deoxy-2-fluoro-D-glucose positron emission tomography (18F-FDG PET)/CT. However, because the tumor was found to have gradually enlarged at 18 months afterward, he underwent resection of the extrarenal fat tissue together with the right kidney. Patient 2 : A 56-year-old man underwent abdominal ultrasound during a periodic medical examination, which revealed a right retroperitoneal tumor. Because of the findings in the contrast-enhanced CT and positive uptake of 18F-FDG PET/CT, he underwent resection of the extrarenal fat tissue together with the right kidney. The pathological examination of the two tumors confirmed extrarenal angiomyolipoma. The differential diagnosis of extrarenal retroperitoneal angiomyolipoma from retroperitoneal liposarcoma is difficult even with the use of 18F-FDG PET/CT.

PubMed

[Outcome of Resection of Inferior Vena Cava Superior to the Renal Vein in Renal Cell Carcinoma with Vena Caval Tumor Thrombus].

Soki Kashima, Shintaro Narita, Mitsuru Saito, Makoto Takahashi, Shinya Maita, Hiroshi Tsuruta, Kazuyuki Numakura, Atsushi Maeno, Takamitsu Inoue, Norihiko Tsuchiya, Shigeru Satoh, Hiroshi Yamamoto, Yuzo Yamamoto, Tomonori Habuchi

Hinyokika kiyo. Acta urologica Japonica 62 ( 6 ) 287 - 94 2016年06月

Surgical management with radical nephrectomy and thrombectomy has often been performed in renal cell carcinoma (RCC) with tumor thrombus infiltrating the inferior vena cava (IVC). We retrospectively reviewed the outcomes of IVC resection without venous reconstruction in patients with RCC and IVC thrombus at our institution. Eight patients with right RCC underwent radical nephrectomy and IVC resection superior to the level of the renal vein without venous reconstruction from August 2005 to February 2015. Thoracotomy, liver mobilization, and extracorporeal circulation were performed based on the IVC thrombus level. We assessed surgical outcomes, perioperative complications, and survival. At presentation, four patients had level IIIa IVC thrombus, three had level IIIb IVC thrombus, and one had level IV IVC thrombus. Perioperative imaging showed that three of the four patients who underwent neoadjuvant molecular targeting therapy achieved down-staging of the tumor thrombus level. The median operative time was 406 min, and the median estimated blood loss was 3,135 ml. With regard to IVC resectionassociated perioperative complications, one patient needed extracorporeal circulation with IVC ligation and Pringle maneuver owing to low blood pressure. Another patient underwent temporary hemodialysis for 8 days after surgery. There were no perioperative deaths, and none of the patients required permanent hemodialysis. Three patients survived the mean observation period of 25 months, including one patient with no recurrence. Three patients achieved long-term survival of more than 2 years. IVC resection without venous reconstruction may be a feasible option for patients with RCC and IVC tumor thrombus. Further study is needed to determine the most appropriate candidates for this procedure.

PubMed

A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer.

Shintaro Narita, Takuya Koie, Shigeyuki Yamada, Kazuhiko Orikasa, Shigeki Matsuo, Hiroshi Aoki, Shigeto Ishidoya, Senji Hoshi, Norihiko Tsuchiya, Chikara Ohyama, Yoichi Arai, Tomonori Habuchi

Japanese journal of clinical oncology 46 ( 6 ) 547 - 553 2016年06月

OBJECTIVE: The optimal schedule of docetaxel chemotherapy for castration-resistant prostate cancer is unknown, although continuous administration is accepted as the standard. We conducted a Phase II trial to evaluate the outcome of intermittent docetaxel and prednisolone therapy in castration-resistant prostate cancer. METHODS: The patients were treated using a 28-day cycle of docetaxel (70 mg/m2 on Day 1) and oral prednisolone (10 mg/day). After three consecutive administrations of docetaxel, a holiday was taken until prostate specific antigen levels returned to the baseline. The therapy was continued intermittently until the disease progressed, drug toxicity occurred, or the patients refused further treatment. The primary endpoint was overall survival. Time to treatment failure, adverse events, the duration of chemotherapy holiday and quality of life were also evaluated. RESULTS: A total of 120 patients were enrolled. The median age and pretreatment prostate specific antigen level were 72 years and 37.5 ng/ml, respectively. Sixty (50.0%) patients resumed chemotherapy after the first holiday, and a maximum of six courses were administered to four patients. The median period of the first, second and third-to-fifth holiday was 18.6, 11.0 and 4.9 weeks, respectively. Toxicity was moderate, except for two fatal adverse events. The median time to treatment failure and overall survival from the initiation of docetaxel and prednisolone therapy in all patients were 17.5 and 35.0 months, respectively. All quality-of-life scores were unchanged statistically from the start of docetaxel and prednisolone therapy to the beginning of the second course. CONCLUSIONS: Intermittent docetaxel and prednisolone therapy might be a feasible treatment option for castration-resistant prostate cancer with comparable outcome and successful chemotherapy holidays.

DOI PubMed

進行性腎癌におけるアキシチニブの効果予測を目的とした血清バイオマーカーの探索

喜早祐介, 本間直子, 鶴田大, 沼倉一幸, 前野淳, 齋藤満, 成田伸太郎, 井上高光, 佐藤滋, 羽渕友則

日本DDS学会学術集会プログラム予稿集 ( 日本DDS学会 ) 32回 197 - 197 2016年06月

[Recent trend in the development of novel treatments based on the mechanisms of prostate cancer progression].

Takamitsu Inoue, Shintaro Narita, Tomonori Habuchi

Nihon rinsho. Japanese journal of clinical medicine 74 Suppl 3 211 - 20 2016年05月

PubMed

[Treatment strategy for high-risk localized prostate cancer].

Shintaro Narita, Takamitsu Inoue, Tomonori Habuchi

Nihon rinsho. Japanese journal of clinical medicine 74 Suppl 3 693 - 700 2016年05月

PubMed

成田伸太郎, 井上高光, 羽渕友則

日本臨床 ( (株)日本臨床社 ) 74 ( 増刊3 新前立腺癌学 ) 693 - 700 2016年05月

井上高光, 成田伸太郎, 羽渕友則

日本臨床 ( (株)日本臨床社 ) 74 ( 増刊3 新前立腺癌学 ) 211 - 220 2016年05月

当科における尿道狭窄に対する尿道形成術5例の検討

本間直子, 井上高光, 鶴田大, 前野淳, 齋藤満, 成田伸太郎, 土谷順彦, 羽渕友則

泌尿器外科 ( 医学図書出版(株) ) 29 ( 臨増 ) 934 - 934 2016年05月

秋田大学における肝転移を有する進行性腎癌の分子標的薬治療成績

五十嵐龍馬, 土谷順彦, 成田伸太郎, 井上高光, 齋藤満, 鶴田大, 前野淳, 高山孝一朗, 佐藤滋, 羽渕友則

泌尿器外科 ( 医学図書出版(株) ) 29 ( 臨増 ) 911 - 911 2016年05月

腎移植治療の最前線秋田大学におけるLESSドナー腎採取術への取り組み

井上高光, 成田伸太郎, 齋藤満, 鶴田大, 沼倉一幸, 前野淳, 佐藤滋, 羽渕友則

泌尿器外科 ( 医学図書出版(株) ) 29 ( 臨増 ) 871 - 874 2016年05月

腹腔鏡下/ロボット支援膀胱全摘除術における尿路変向術の現状と問題点腹腔鏡下/ロボット支援膀胱全摘除術における尿路変向完全体腔内と小切開体腔外での造設法の比較

井上高光, 成田伸太郎, 齋藤満, 鶴田大, 沼倉一幸, 前野淳, 佐藤滋, 羽渕友則

泌尿器外科 ( 医学図書出版(株) ) 29 ( 臨増 ) 741 - 743 2016年05月

EXOSOMAL MIRNAS AND SERUM CYTOKINES AS PREDICTORS FOR TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH AXITINIB

Naoko Suzuki-Honma, Norihiko Tsuchiya, Takamitsu Inoue, Shintaro Narita, Mitsuru Saito, Hiroshi Tsuruta, Atsushi Maeno, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 195 ( 4 ) E322 - E323 2016年04月

研究発表要旨（国際会議）

EXPRESSION OF STEROID HORMONE RECEPTORS IN RESIDUAL CANCER AND STROMAL CELLS AFTER NEOADJUVANT CHEMOHORMONAL THERAPY WITH DOCETAXAL FOR HIGH-RISK LOCALIZED PROSTATE CANCER

Shintaro Narita, Taketoshi Nara, Mingguo Huang, Koichiro Takayama, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchiya, Hiroshi Nanjo, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 195 ( 4 ) E759 - E760 2016年04月

研究発表要旨（国際会議）

PROTECTIVE EFFECTS OF REGULATORY T CELLS IN RENAL ISCHEMIA/REPERFUSION INJURY IN MICE

Ryohei Yamamoto, Mitsuru Saito, Hiroshi Tsuruta, Atsushi Maeno, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 195 ( 4 ) E383 - E383 2016年04月

研究発表要旨（国際会議）

REASSESSMENT OF RISK FACTORS FOR BIOCHEMICAL RECURRENCE IN D'AMICO INTERMEDIATE-RISK PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY

Shintaro Narita, Koji Mitsuzuka, Norihiko Tsuchiya, Takuya Koie, Sadafumi Kawamura, Chikara Ohyama, Tatsuo Tochigi, Takuhiro Yamaguchi, Yoichi Arai, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 195 ( 4 ) E712 - E713 2016年04月

研究発表要旨（国際会議）

Rising star report 移植腎採取術の低侵襲化への挑戦

井上高光, 成田伸太郎, 齋藤満, 鶴田大, 佐藤滋, 羽渕友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 104回 SPS14 - 2 2016年04月

Stage D2前立腺癌に対する内分泌療法前および治療早期の予後予測因子の検討

成田伸太郎, 佐藤博美, 鶴田大, 前野淳, 斉藤満, 井上高光, 土谷順彦, 佐藤滋, 羽渕友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 104回 PP1 - 082 2016年04月

　前のページ - 次のページ　

<成田 伸太郎>

研究等業績 - その他 - 成田 伸太郎

<成田　伸太郎>

研究等業績 - その他 - 成田　伸太郎